ARTICLE | Company News
RiboGene other research news
April 24, 1995 7:00 AM UTC
The Hayward, Calif., company received a $100,000 Phase I SBIR from the National Institute of Allergy and Infectious Diseases to develop antivirals using its translation-based drug discovery technology...